STAAR Surgical Co. - 10-Q Summary (Quarter Ended April 2, 1999)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended April 2, 1999, for STAAR Surgical Company, a Delaware corporation based in Monrovia, California. The company manufactures and sells refractive products, including the Implantable Contact Lens (ICL) and Toric intraocular lenses. As of May 12, 1999, the company had 14,029,811 shares of common stock issued and outstanding.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Total Revenues | $14,783,139 | $14,100,869 |
| Gross Profit | $9,038,469 | $9,817,180 |
| Gross Margin | 61.1% | 69.6% |
| Operating Income | $1,387,788 | $2,733,499 |
| Net Income | $672,751 | $1,674,888 |
| Diluted EPS | $0.05 | $0.12 |
| Cash and Equivalents (End of Period) | $4,103,046 | $3,593,960 |
| Net Cash from Operating Activities | ($19,659) | $4,250,840 |
| Total Debt (Current + Long-term) | $12,308,401 | N/A |
| Current Ratio | 3.1:1 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 4.8% year-over-year, driven by higher sales of refractive products (ICL and Toric lenses). This was partially offset by lower average selling prices for intraocular lenses (IOLs) due to competitive pressures.
- Margin Compression: Gross margin declined from 69.6% to 61.1%. Cost of sales rose to 38.9% of revenue from 30.4%, attributed to lower IOL selling prices and higher unit costs from lower production volumes in the prior year.
- Profitability Decline: Net income dropped 59.8% to $672,751. Operating income fell 49.2% due to increased marketing expenses for the Toric lens launch and higher interest expenses.
- Cash Flow Shift: Operating cash flow turned negative at ($19,659), a significant reversal from the $4.25 million positive flow in the prior year, primarily due to a $1.66 million increase in operating working capital.
- Liquidity: Cash and cash equivalents decreased by approximately $0.6 million during the quarter. However, the current ratio improved to 3.1:1, and net working capital increased to $28.3 million.
Outlook, Risks, and Management Commentary
- Management Outlook: Management expects the company to remain profitable in the future, with cash flow needs met by operations or additional financing if required.
- Year 2000 Compliance: The company is ahead of schedule for Year 2000 compliance. Principal hardware and software have been certified or upgraded. Costs incurred to date are immaterial, though risks remain regarding third-party vendors and utilities.
- Foreign Operations: Foreign sales totaled approximately $8.5 million (57.7% of revenue), primarily in Europe. Risks include fluctuating exchange rates and foreign government regulations.
- Unusual Items: An officer exercised stock options in exchange for a $405,625 note secured by a stock pledge, maturing in 2003.
Investor Verification Checklist
- Verify the sustainability of the 4.8% revenue growth given the 8.5% decline in gross margin.
- Confirm the impact of the $1.66 million increase in working capital on future operating cash flows.
- Assess the competitive landscape for IOLs and the effectiveness of the Toric lens launch in offsetting price erosion.
- Review the status of Year 2000 compliance for critical suppliers and vendors, as noted in the risk factors.
- Monitor the company's ability to maintain a current ratio above 3.0 while managing debt obligations totaling over $12 million.